Skip to main content

Table 1 Main characteristics of the economic evaluation studies.

From: Burden of disease and economic evaluation of healthcare interventions: are we investigating what really matters?

Characteristics n (%)
Study type  
Cost-effectiveness analysis (CEA) 298 (62.5)
Cost-minimization analysis (CMA) 78 (16.4)
Cost-utility analysis (CUA) 73 (15.3)
Cost-benefit analysis (CBA) 28 (5.9)
Health research activities  
Prevention of disease and conditions, and promotion of well-being 83 (17.4)
Medically oriented (e.g. chemoprevention, vaccines) 78 (16.4)
Education/behaviour 5 (1.0)
Detection, screening and diagnosis 53 (11.1)
Screening 48 (10.1)
Resources and procedures 5 (1.0)
Treatments and therapeutic interventions 334 (70.0)
Medically oriented (e.g. pharmaceuticals) 263 (55.1)
Devices and procedures 33 (6.9)
Surgery 28 (5.9)
Education/behaviour 10 (2.1)
Rehabilitation 7 (1.5)
Methods  
Decision analysis 162 (34.0)
Observational studies 111 (23.3)
Not explicit 88 (18.4)
Markov or other simulation models 74 (15.5)
Clinical trials 42 (8.8)
Perspective adopted  
Healthcare system 201 (42.1)
Non explicit 121 (25.4)
Hospital 93 (19.5)
Society 59 (12.4)
Others 3 (0.6)
Costs  
Direct 404 (84.7)
Direct and indirect 73 (15.3)
Cost information  
Explicit 359 (75.3)
Non explicit 118 (24.7)
Funding source  
Non explicit 210 (44.0)
For profit 205 (43.0)
Non for profit 62 (13.0)
Affiliation of the first author  
Hospital 243 (50.9)
Private (e.g. consulting, pharmaceutical industry) 99 (20.7)
University 56 (11.7)
Administration 55 (11.5)
Primary care 17 (3.6)
Non explicit 7 (1.5)
Recommendations  
Yes 392 (82.2)
No 85 (17.8)